Here, our work also confirmed that the responsiveness of HCC to anti-PD-1 antibody was associated with the number and activation of M1-like TAMs and CD8+ T cells including stem-like CD8+ T cells, indicating that the reprogramming of M2-like TAMs to M1-like phenotype might help to improve the therapeutic efficacy of anti-PD-1 antibody. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.